Literature DB >> 8736618

Practical guidelines for the treatment of cholera.

C Seas1, H L DuPont, L M Valdez, E Gotuzzo.   

Abstract

Cholera is a dramatic clinical illness that requires rapid diagnosis and aggressive therapy. Clinical signs and symptoms of mild, moderate and severe dehydration must be determined, before beginning fluid therapy. Fluid therapy has 2 phases: rehydration (first 3 to 4 hours to correct deficits) and maintenance (to match continuing losses). The route and speed of fluid administration will depend on the degree of dehydration. Patients with severe dehydration should be treated intravenously, as should those patients who do not tolerate oral rehydration solution (ORS). Ringer's lactate is the preferred intravenous solution, although normal saline may be used along with ORS. For most patients with cholera, an ORS using one of the higher sodium-containing solutions and plain water optimally provide the fluid and salt needed. Close monitoring of intake, outputs and hydration status should be performed for all patients. Antimicrobial therapy should be given to moderately and severely ill patients in order to decrease the volume of fluids lost and to shorten the period of excretion of vibrios.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8736618     DOI: 10.2165/00003495-199651060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  17 in total

1.  Cholera in 1991.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1992-08-21

2.  TETRACYCLINE IN THE TREATMENT OF CHOLERA.

Authors:  W B GREENOUGH; R S GORDON; I S ROSENBERG; B I DAVIES; A S BENENSON
Journal:  Lancet       Date:  1964-02-15       Impact factor: 79.321

3.  Progress in oral rehydration therapy.

Authors:  N Hirschhorn; W B Greenough
Journal:  Sci Am       Date:  1991-05       Impact factor: 2.142

Review 4.  Chemoprophylaxis studies in cholera: a review of selective works.

Authors:  S Ghosh; P G Sengupta; D N Gupta; B K Sirkar
Journal:  J Commun Dis       Date:  1992-03

Review 5.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

6.  Vibrio cholerae non-O1--the eighth pandemic?

Authors:  D L Swerdlow; A A Ries
Journal:  Lancet       Date:  1993-08-14       Impact factor: 79.321

7.  Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh.

Authors: 
Journal:  Lancet       Date:  1993-08-14       Impact factor: 79.321

8.  Rapid emergence of El Tor Vibrio cholerae resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania.

Authors:  F S Mhalu; P W Mmari; J Ijumba
Journal:  Lancet       Date:  1979-02-17       Impact factor: 79.321

Review 9.  Cholera. Lessons from the epidemic in Peru.

Authors:  E Gotuzzo; J Cieza; L Estremadoyro; C Seas
Journal:  Infect Dis Clin North Am       Date:  1994-03       Impact factor: 5.982

10.  Clinical characteristics and risk factors for Vibrio cholerae infection in children.

Authors:  J M Fukuda; A Yi; L Chaparro; M Campos; E Chea
Journal:  J Pediatr       Date:  1995-06       Impact factor: 4.406

View more
  5 in total

Review 1.  Tetracyclines and bone: Unclear actions with potentially lasting effects.

Authors:  Amy J Warner; Jessica D Hathaway-Schrader; Rena Lubker; Christopher Davies; Chad M Novince
Journal:  Bone       Date:  2022-03-03       Impact factor: 4.626

Review 2.  Antimicrobial drugs for treating cholera.

Authors:  Ya'ara Leibovici-Weissman; Ami Neuberger; Roni Bitterman; David Sinclair; Mohammed Abdus Salam; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2014-06-19

3.  Identification of Widespread Antibiotic Exposure in Patients With Cholera Correlates With Clinically Relevant Microbiota Changes.

Authors:  Ludmila Alexandrova; Farhana Haque; Patricia Rodriguez; Ashton C Marrazzo; Jessica A Grembi; Vasavi Ramachandran; Andrew J Hryckowian; Christopher M Adams; Md Shah A Siddique; Ashraful I Khan; Firdausi Qadri; Jason R Andrews; Mahmudur Rahman; Alfred M Spormann; Gary K Schoolnik; Allis Chien; Eric J Nelson
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

4.  Bovine Lactoferrin and Lactoferrin-Derived Peptides Inhibit the Growth of Vibrio cholerae and Other Vibrio species.

Authors:  Erika Acosta-Smith; Karina Viveros-Jiménez; Adrian Canizalez-Román; Magda Reyes-Lopez; Jan G M Bolscher; Kamran Nazmi; Hector Flores-Villaseñor; Gerardo Alapizco-Castro; Mireya de la Garza; Jesús J Martínez-Garcia; Jorge Velazquez-Roman; Nidia Leon-Sicairos
Journal:  Front Microbiol       Date:  2018-01-11       Impact factor: 5.640

Review 5.  Severe acute diarrhea.

Authors:  Julia I Gore; Christina Surawicz
Journal:  Gastroenterol Clin North Am       Date:  2003-12       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.